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Vascular complicationsAbstract Objective: This study was performed to evaluate the feasibility and safety of early sheath
removal after percutaneous coronary intervention (PCI) using a locally designed Assiut Femoral
Compression Device (AFCD2) vs. manual compression (MC).
Background: Due to antithrombotic therapy before, during, and after PCI, the arterial femoral
sheath is generally not removed early after PCI.
Patients and methods: This was a randomized, controlled trial. We enrolled all patients undergoing
PCI at Assiut University Hospitals from September, 2013 to December, 2013. At the end of PCI,
the arterial hemostasis method was randomly assigned 1:1 to AFCD2 vs. MC. The sheaths were
removed 2 h after PCI, instead of conventional 6 h, in the AFCD2 arm.
Results: The trial assigned 100 patients (mean age 57 ± 9 years, 75% men) to AFCD2 (n= 50) vs.
MC (n= 50). Both groups were comparable regarding baseline characteristics. Concerning the pri-
mary effectiveness end point, there was signiﬁcantly shorter mean time-to-ambulation with AFCD2
(8.2 ± 1.42 h) vs. MC (12.02 ± 0.22 h; p=<0.001). This was directly reﬂected on shorter time for
hospital discharge eligibility in AFCD2 (11 ± 1 h) vs. MC (15 ± 1 h; p=<0.001). As regards
safety, none of our research population experienced major adverse events. The use of AFCD2
was associated with similar occurrence of minor complications, mainly ecchymosis and oozing,
compared with MC.333327.
70 A.K.M. Hassan et al.Conclusion: Our results indicate that AFCD2 is a simple and effective alternative to MC for
hemostasis following PCI. Early sheath removal 2 h post PCI is feasible, safe, and improves the
patient’s comfort.
ª 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of
Cardiology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).1. Introduction
Percutaneous coronary intervention (PCI) is inevitably associ-
ated with the risk of access site complications as high as
16%,1–4 especially with the aggressive antithrombotic treat-
ment required for stenting. Although trans-radial coronary
angioplasty has been shown to be safe and to decrease the rate
of access site complications,5 it has not gained wide popularity
and most of the procedures are currently performed via the
femoral route at Assiut University Hospitals (AUH). After a
trans-femoral PCI procedure, the arterial sheath is usually
removed after 4–6 h in order to wait for heparin reversal.
Then, a period of bed rest of a minimum of 6 h is advised,
and this period of immobilization makes the procedure more
uncomfortable for the patient.6 Assiut Femoral Compression
Device (AFCD1) is a locally designed femoral compression
system with proven safety and efﬁcacy compared to manual
compression (MC) on 206 patients undergoing coronary
angiography.7
At AUH, we use only conventional MC to achieve hemos-
tasis in high risk patients undergoing PCI. After our primary
report, we collaborated with Mechatronic Engineering Depart-
ment, to develop AFCD2 with improved quality and efﬁcacy.7
At this second report, we evaluated the efﬁcacy and safety
of early sheath removal after PCI using AFCD2 compared to
MC in a randomized controlled trial.2. Methods
2.1. Trial design and patient selection
We performed a randomized, controlled, nonblinded trial with
parallel assignment and 1:1 allocation, at the catheterization
laboratory of Assiut University Hospitals. Patients between
18 and 85 years of age, scheduled to undergo an elective PCI
via arterial puncture of common femoral artery were eligible
for enrollment in the study. Elective PCI was deﬁned as any
coronary revascularization in a low-risk patient who presents
to the facility for a planned PCI or for a coronary angiogram
followed by ad hoc PCI.8,9 Patients were excluded from the
trial if the patient has any procedural complication: included
prolonged chest pain, transient closure, no-ﬂow or slow-ﬂow
phenomenon, hemodynamic instability, persistent electrocar-
diographic changes, side-branch occlusion of >1.5 mm, or
an angiographically suboptimal result, arterial access other
than the right or left femoral artery, vascular perforation,
thrombosis during procedure, patients with high risk of punc-
ture site complications as: bleeding diathesis, international
normalized ratio >1.5, recent thrombolysis, low platelet
count, lower limb atherosclerosis, previous iliofemoral artery
surgery or any peripheral vascular surgery, previous femoralartery complication from angiography, and uncontrolled
hypertension at time of procedure (>180/>110).
2.2. Study groups and protocol
From September, 2013 to December, 2013, 150 patients who
underwent elective PCI via arterial puncture of common fem-
oral artery were assessed for eligibility. 50 patients were
excluded (Fig. 1). 100 patients were randomized into two
groups with 1:1 allocation concealment using daily numbered,
sealed envelopes: 50 patients used AFCD2 and 50 patients
used MC for arterial hemostasis. The trial protocol was
reviewed and approved by the institutional review committee,
and all patients granted their informed consent to be included
in the trial. The demographic and clinical data were collected
using a standardized ‘‘procedural datasheet’’.
2.2.1. PCI procedure
PCI was performed using femoral approach in all our patients
using 6 F guiding catheters. All patients had detailed history
and clinical examination to exclude bleeding diathesis with
complete blood picture before procedure. All patients were
pre-treated with aspirin 150 mg and clopidogrel 600 mg orally
before the procedure. The anticoagulation protocol included
intravenous heparin bolus 10,000 U. No activated clotting
time (ACT) was measured during or after intervention. Glyco-
protein IIb/IIIa inhibitors were used according to the operator
discursion. Stent implantation was at the discretion of the pri-
mary operator. None of our patients received protamine sul-
fate for reversal of anticoagulation.
2.2.2. Vascular access management
The intra-arterial sheaths were removed 6 h after PCI in the
MC group according to the standard local protocols. However
for the AFCD2 group, the sheaths were removed 2 h after PCI
instead of conventional 6 h. To standardize compression times,
AFCD2 was applied to patient and complete femoral artery
compression was applied for 5 min, followed by a gradual
release of pressure till distal pulse is palpated. Each patient
received a minimum of 13 min of compression, with further
compression applied only if full hemostasis had not been
achieved at that point with maximum of 30 min.
2.2.3. Post-procedure care
Immediately after achieving hemostasis, arterial access site was
carefully inspected for evidence of hematoma formation or
other vascular problems. Then a pressure dressing using ban-
dage was applied to maintain hemostasis. After PCI, patients
were observed in the department ward by staff that is well
trained to manage post-PCI complications. Post-interventional
therapy included 150 mg/day of aspirin and 75 mg/day of
Figure 1 Flow of patients through the trial. AFCD=Assiut Femoral Compression Device.
Figure 2 Assiut Femoral Compression Device 2 Design. (1)
White textile belt (2 m) with adhesive stickers on both sides, (2)
Galvanized Steel Sheet, (3) Metallic screw (19 cm) with more snails
and (4) Wood with ﬂat surface pressure dome.
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1 year in case of a drug eluting stent.
2.2.4. Ambulation
Uniform verbal instructions of immobility were given to each
patient with bed rest for 6 h after the procedure. All dressings
were removed and all patients were strongly encouraged to
ambulate 6 h after sheath removal. Vital sign check, vascular
access site, and distal vascular bed examination by ultrasonog-
raphy were done immediately after ambulation for a compre-
hensive analysis before discharge.
2.2.5. Pre-discharge evaluation
Suitability for discharge required freedom from symptoms,
absence of electrocardiogram changes, absence of puncture site
abnormalities and successful ambulation. Written instructions
and oral explanation of all possible events were given to all
patients. Before discharge, patients were instructed on how
to achieve hemostasis by local pressure for puncture-related
bleeding. All patients received pre-discharge counseling on diet
and lifestyle modiﬁcation. The management of medication
compliance was repeatedly highlighted by the interventionalist
and residents directly involved in the patient care. With suc-
cessful ambulation, patients were instructed to climb only 1
ﬂight of stairs and not to lift heavy objects for 3 days after
the procedure.
2.3. Device description
The ﬁrst version of Assiut Femoral Compression Device
(AFCD1) has been described in detail in our primary report.7
Dissimilarity between AFCD1 and the second version AFCD2
used in this trial is presented in Fig. 2: (a) The material used for
the arch is Galvanized Steel Sheet which is more powerful than
72 A.K.M. Hassan et al.Plexiglass used in AFCD1, (b) More potent pressure dome
that is made of wood with ﬂat surface rather than plexiglass
with cone shaped surface in AFCD1, (c) Longer metallic
screw: 19 cm (instead of 15 cm in AFCD1) with more snails
for rapid screw movements, (d) Longer and stronger belt made
of 2 m (instead of 1.5 m in AFCD1) of white strong textile with
adhesive stickers on both sides (instead of black fabric with
plastic fastener in AFCD1) and no elongation kit (Fig. 2).23
Our AFCD total cost is around 15 $ once. It can be reused
with discard of the sterile disposable gloves positioned over
the dome.
2.4. Study end points
2.4.1. The primary efﬁcacy end point of the study was
1- Time-to-ambulation (TTA), measured in hours.
TTA was measured from the time the introducer sheath was
removed to the time of ambulation. Ambulation was deﬁned as
patient standing and walking at least 6 m (20 feet) without re-
bleeding or signiﬁcant oozing requiring manual compression.
2- Time the patient is deemed eligible for hospital discharge
Measured from the time of access site closure to the time
when the patient was judged by the attending physician to be
ready for discharge from the hospital. Hospital discharge deci-
sion was at the discretion of the primary operator and the
attending physician irrespective of the patient’s assignment
to one of the hemostasis techniques.
2.4.2. The secondary efﬁcacy end point of the study was
1. Time-To-Hemostasis (TTH), measured in minutes
TTH was measured from the time the introducer sheath
was removed to the time hemostasis was achieved. Hemostasis
was deﬁned as no or minimal subcutaneous oozing and the
absence of expanding or developing hematoma.10 The entry
site was revised for signs of active bleeding (acknowledged as
failure of closure strategy). In case of failure, the compression
was restored manually for additional 2–5 min. and observed
thereafter until bleeding stops.Figure 3 Primary effectiveness endpoint: time-to-ambulation in
the AFCD2 group compared to those with MC. Time-to-ambu-
lation showed a highly signiﬁcant difference between the two
groups (p< 0.001). MC =manual compression; AFCD= Assi-
ut Femoral Compression Device.2. Device success
This was deﬁned as easy application of the device with good
ﬁxation and stability and achieving ﬁnal hemostasis. Time for
device deployment was measured from the beginning to posi-
tion the belt under the patient till the removal of the femoral
sheath. Device stability was deﬁned as the absence of tilt
and/or mobility after application of the device on top of the
patient groin. Assessment of the device application was per-
formed using a questionnaire with a scale of three grades;
‘‘Easy’’, ‘‘Difﬁcult’’ and ‘‘Requires Improvement’’. Assessment
of stability and ﬁxation of the device was performed on a scale
deﬁned as ‘‘Very Good’’, ‘‘Good’’ and ‘‘Bad’’.
3. Procedure success
This was deﬁned as hemostasis achieved by the assigned
method, without the occurrence of a closure-related major
adverse event (MAE).MAE was deﬁned as symptomatic bleed-
ing associated with hemoglobin dropP5 g/dL requiring blood
transfusion, fatal bleeding that directly results in death, a pseu-
doaneurysm or arteriovenous ﬁstula, distal arterial embolism,
infections requiring administration of IV antibiotics or
debridement, and the need for vascular surgery.10,11
2.4.3. The primary safety end point was deﬁned as the absence of
MAE on discharge
2.4.4.1. The secondary safety end points included.
1. Minor complications
Any oozing (leakage of blood from the puncture site requir-
ing digital pressure), ecchymosis (bleeding into subcutaneous
tissue planes causing bluish-purple discoloration >4 cm in
diameter), hematoma (non pulsatile mass >1 cm in diameter),
and infections treatable with oral antibiotics.11,12
2. Patient discomfort
Patients were asked about the intensity of pain during the
hemostasis procedure. Patient discomfort was assessed based
on a short form of the McGill Pain Questionnaire using a Pres-
ent Pain Intensity (PPI) scale that rated pain from 0 (no pain)
to 5 (excruciating).11
3. Vasovagal manifestations (sweating, bradycardia, nausea
and vomiting): were recorded
2.5. Sample size calculation
The trial was designed to have a 95% power to detect a 5.5 h
difference in time-to-ambulation (TTA) with an overall type I
error rate of 0.05 (two sided). Sample size was calculated to be
at least 50 patients in each arm. Mean TTA was estimated to
be 8 h in the AFCD2 group and 12 h in the MC group with
a common standard deviation (sigma) of 5.5 h.13
2.6. Randomization process
At the completion of PCI, patients were randomly assigned to
AFCD2 vs. MC, using sealed envelopes in a 1:1 allocation
sequence. The assignment was based on simple randomization
of procedure on daily basis. The enrollment period of the trial
lasted 3 months, and the patient clinical follow-up was 24 h
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PCI, and were managed and analyzed by a blinded statistician.
If all the criteria for entry in the trial were satisﬁed, an enve-
lope was opened to randomly assign the patient to AFCD2
or MC.
2.7. Statistical analysis
Categorical data were presented as counts and proportions
(percentages) and compared by Pearson chi-square analysis
or Fischer’s exact test if the expected cell count for a 2 · 2 table
was <5. Normal distribution of continuous data was tested
using a Kolmogorov–Smirnov test. Continuous and normally
distributed data are presented as mean ± 1 standard deviation
and were compared by two-tailed unpaired t-test. These com-
parisons were performed using the SPSS version 16.0 software
package (SPSS Inc., Chicago, IL), and a p value of 60.05 was
considered to be signiﬁcant.
3. Results
3.1. Patient characteristics
The baseline demographic and clinical characteristics of the 2
trial groups are summarized in Table 1. The two groups were
comparable with no signiﬁcant differences in baseline andTable 1 Baseline clinical and procedural characteristics of the stud
Variable MC (N= 50)
Age (years) 56 ± 10
Male gender n (%) 38 (76%)
Smoking n (%) 31 (29.2%)
Hypertension n (%) 21 (42%)
Dyslipidemia n (%) 30 (28.3%)
Diabetes mellitus n (%) 22 (44%)
PAD 0
Chronic renal impairment 0
Previous PCI 4 (8%)
Previous CABG 3 (6%)
Weight (kg) 80 ± 13
Height (m) 165 ± 9
Body mass index n (%)
From 18.5 to 25 kg/m2 12 (24%)
From 25 to 30 kg/m2 24 (48%)
>30 kg/m2 14 (28%)
Previous femoral puncture 17 (34%)
Prothrombin concentration % 94 ± 7
INR 1 ± 0.1
Hemoglobin (mg/dl) 12 ± 2
Platelets (u/L) 272 ± 87
INR impaired n (%) 0
Warfarin before hospital admission 0
Chronic aspirin therapy 47 (94%)
Chronic clopidogrel therapy 22 (44%)
Number of diseased vessels 1.6 ± 0.5
Number of stents 1.6 ± 0.5
Number of DES 22 (44.9%)
Need GP 2b/3a 0
Complicated procedure 1 (2%)
Data are presented as mean ± standard deviation, number (%) of pat
pression Device; IHD= ischemic heart disease; NS = not signiﬁcant;
intervention; IND= international normalized ration; DES = drug elutinprocedural characteristics. Approximately three-quarters of
patients in each group were men. Obese patients with a body
mass index >30 kg/m2 tend to be higher in the AFCD2 group
(36%) compared to 28% of patients in the MC groups
(p=NS). Procedural variables are shown in Table 1 with no
difference in use of GP2B/3A, neither number nor type of
stents used.
3.2. Analysis of efﬁcacy
Concerning the primary effectiveness end point, the mean TTA
was signiﬁcantly shorter in the AFCD2 group compared to the
MC group with a mean difference of around 4 h (8.2 ± 1.42
vs. 12.02 ± 0.22 h; p=<0.001). This was directly reﬂected
on shorter time for hospital discharge eligibility in the AFCD2
group (Fig. 3). On the other hand, the mean TTH was longer
in the AFCD2 group compared to the MC group (27.3 ± 4.3
vs. 22.3 ± 5.4 min; p=<0.001). However, the mean differ-
ence was only 5 min. The duration of hospital stay did not dif-
fer between groups (Table 2).
The procedure success was observed in 48 (96%) patients of
the AFCD2 group and all patients of the MC group. None of
our research population experienced a MAE.
The device success was observed in 48 patients of the
AFCD2 group with mean device deployment time ofy population.
AFCD2 (N= 50) P
57 ± 9 NS
37 (74%) NS
37 (37%) NS
23 (46%) NS
31 (31%) NS
16 (32%) NS
0 0
0 0
1 (2%) NS
0 NS
77 ± 12 NS
164 ± 7 NS
11 (22%) NS
21 (42%)
18 (36%)
13 (26%) NS
92 ± 10 NS
1 ± 0.1 NS
12 ± 2 NS
261 ± 66 NS
0 0
0 0
50 (100%) NS
28 (56%) NS
1.6 ± 0.5 NS
1.6 ± 0.5 NS
17 (35.4%) NS
1 (2%) NS
1 2%) NS
ients. MC=manual compression; AFCD= Assiut Femoral Com-
PAD= peripheral arterial disease; PCI = percutaneous coronary
g stents; GP 2b/3a = glycoprotein 2b/3a inhibitors.
Table 2 Effectiveness and safety results in the study groups.
Parameter MC AFCD2 P
(N= 50) (N= 50)
Time to ambulation (h) 12.02 ± 0.22 8.2 ± 1.4 <0.001
Eligibility for hospital discharge (h) 15 ± 1 11 ± 1 <0.001
Time to Hemostasis (min) 22.3 ± 5.4 27.3 ± 4.3 <0.001
Hospital discharge (h) 23 ± 9 23 ± 5 0.96
Vagal episodes 1 (2%) 6 (12%) 0.056
Hematoma size <5 cm 7 (14%) 4 (8%) 0.33
Hematoma 1 cm 1 (2%) 0
Hematoma 2 cm 3 (6%) 1 (2%)
Hematoma 3 cm 1 (2%) 2 (4%)
Hematoma 4 cm 2 (4%) 1 (2%)
Hematoma >5 cm/major bleeding 1 (2%) 0 0.31
Ecchymosis 16 (32%) 14 (28%) 0.66
Oozing 2 (4%) 5 (10%) 0.24
Peripheral ischemia 0 0
Retroperitoneal hematoma 0 0
Pseudo aneurysm 0 0
AV ﬁstulae/bruit 0 0
Site infection 0 0
Death 0 0
Major adverse events 0 0
Data are presented as mean ± standard deviation, number (%) of patients or median. MC=manual compression; AFCD2 = Assiut Femoral
Compression Device; AV = arterio-venous; NS = not signiﬁcant.
Figure 4 The scores of pain assessment scale for each patient in
AFCD2 group compared to those with MC. Pain grade showed no
signiﬁcant difference between the 2 groups (p=NS). MC=man-
ual compression; AFCD2 = Assiut Femoral Compression Device.
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(80%) while device ﬁxation was very good in 47 patients (94%).
Only two patients experienced device failure, these patients
crossed over to MC without further vascular complication
because of a device failure. In the ﬁrst case, failure was due
to the development of vasovagal reaction related to pain so
the device was removed and MC was used to complete
hemostasis. In the second case, the device was applied for
the maximum time but hemostasis was not completed and we
needed MC for another 10 min without further vascular
complication.3.3. Regarding safety
No complication was new or unanticipated, and the type of
complication did not differ between the 2 trial arms. None
of our study population reported any MAE.
Some secondary adverse events occurred in each study
group, without statistically signiﬁcant differences among the
groups. The incidence of minor complications was comparable
in both groups (Table 2). These minor complications were
mainly ecchymosis and oozing in both groups. Large hema-
toma >5 cm was noted in 1 pts. (1.8%) in the MC arm vs.
non in the AFCD2 arm (p= 0.3). Size of hematoma in the
MC arm was bigger compared to the AFCD2 arm; however
this difference was not statistically signiﬁcant (Table 2).
3.4. Regarding pain
The tolerance of the hemostasis procedure was good with both
techniques without signiﬁcant difference between the two
groups. The scores of pain assessment scale for each group
are presented in Fig. 4. Patients did not report a signiﬁcant dif-
ference in the pain score in the AFCD2 group compared with
the MC group (p=NS). The incidence of vagal episodes was
slightly higher in the AFCD2 arm compared to the MC arm
(12% vs. 2%; p= 0.056). However, all of these episodes
resolved spontaneously without medications but one patient
in each group needed CCU admission for severe pain and
vagal collapse (Table 2).
4. Discussion
In this randomized controlled trial of a new locally developed
Femoral Compression Device, we could demonstrate a high
procedural success rate, with a signiﬁcantly 4 h shorter time-
to-ambulation and time to hospital discharge eligibility after
Feasibility and safety of early sheath removal 75PCI in the AFCD2 group. There was no signiﬁcant difference
in the complication rate between the study groups. None of
our trial population reported any MAE, conﬁrming that
AFCD2 is a simple, safe and effective alternative to MC for
hemostasis 2 h. following PCI.
Few large studies have compared vascular access strategies
in patients undergoing elective coronary procedures.14–16 Sev-
eral devices have been developed to aid in the closure of the
femoral arteriotomy, including, extravascular plug devices
(VasoSeal, AngioSeal, ExoSeal),10,17 percutaneous suture clo-
sure devices (Perclose, StarClose),18 and mechanical compres-
sion devices.19–23 Mechanical compression devices most
commonly used are the C-clamp or Compressor (Advanced
Vascular Dynamics, Portland, OR) and pneumatic Femostop
device (Radi Medical Systems, Uppsala, Sweden). All these
devices including our AFCD provide the application of con-
stant pressure while maintaining limb perfusion monitored
by only one nurse and free up the operator. However,
increased cost per patient of both Femostop (75–150 $) and
C-clamp (50–100 $) compared with MC was identiﬁed as a dis-
advantage.19,23 Our AFCD total cost is around 15 $ once.
The C-clamp and Femostop devices were compared to MC
in a number of studies,19–21,23 which generally reported equal
efﬁcacy with no signiﬁcant differences regarding femoral vas-
cular complication rates.
Regarding efﬁcacy of AFCD2 by measuring TTA there was
a great decrease (about 4 h) in the AFCD2 group in contrast to
the MC group (8.20 ± 1.42 h vs. 12.02 ± 0.22 h,
p=<0.001). This was the main driving factor for 4 h reduc-
tion in time for hospital discharge eligibility in the AFDC2
group which allows early movement of patients, and reduces
patient discomfort by long bed rest following PCI. Our ﬁnd-
ings are in accordance with Jaspers et al.24 who also reported
a 4 h reduction in TTA after Femostop application but imme-
diately after PCI in 339 patients. Also Wong et al.10 reported a
3.7 h reduction in TTA in the ExoSeal closure device group
compared to manual compression.
Regarding ability to obtain full hemostasis, our trial
showed equal efﬁcacy with a ﬁve min. shorter TTH in the
MC group compared to the AFCD2 group (22.3 ± 5.4 vs.
27.3 ± 4.3 min, p< 0.001), in accordance with Bogart23 who
demonstrated that mean TTH was 22 min for MC and
31 min for mechanical device compression. The increase in
TTH in the AFCD2 group can be explained by early sheath
removal 2 h. after PCI as intended by the trial protocol.
On the other hand, Walker et al.19 showed that TTH was
much shorter in the MC group than the Femostop group. This
can be explained by the difference in the trial design, where
Femostop application protocol was extended for 30 min.
Device failure rate in our trial was 4%, which was in agree-
ment with Femostop device failure rate.19,25 Bogart23 reported
that 13% of cases with compressor device were switched to
MC which is an accepted failure rate.
Concerning patient comfort, the pain level at the time of
sheath removal did not differ signiﬁcantly between our
AFCD2 group compared with the MC group. This was in
agreement with Benson et al.26 who reported that the mean
pain level in the MC group was 1.9 ± 0.5 while in the Com-
pressor group it was 2.1 ± 0.5. On the other hand, Norderh-
aug et al.19 showed that there was more discomfort withFemostop device than with MC as the device application
was for 1 h in all patients compared to 12 min for MC. Also,
Lehmann et al.27 presented that there was more discomfort
with Femostop use (3.1 ± 2.1) compared with MC
(1.9 ± 1.9) or C-clamp (2.2 ± 2.0) (p< 0.001).
Conﬂicting results were also noted regarding safety issue.
Sridher et al. showed lower complication rate in the Femostop
device group compared with the MC group.26 On the other
hand, Lehmann et al.27 concluded that the use of the Femostop
device leads to longer compression times, greater discomfort,
more bleeding, and larger hematomas. In a metaanalysis of
16 randomized clinical studies comparing the rates of access site
complications (excluding hematoma) associated with vascular
closure devices (VCD) vs. MC in over 5000 patients, Vaitkus28
reported a lower risk of vascular complications associated with
VCD. Two other meta-analyses comparing the safety of VCD
with MC, published in 200429,30 found similar rates of peripro-
cedural, access site complication with VCD and MC, whether
the procedure was diagnostic or interventional.
In our trial, no complication was new or unanticipated.
Neither the type nor the incidence of complication differs
between the 2 groups. None of our trial population reported
any MAE. The incidence of small hematoma <5 cm was 8%
in the AFCD2 group vs. 14% in the MC group in accordance
with Lehmann et al.27who showed that the frequency of hema-
toma formation was statistically similar between MC (10%)
and mechanical compression (11% for C-clamp and 13% for
Femostop). However, Walker et al. showed that prevalence
of hematoma was higher in the Femostop group (18.1%) than
in the MC group (9.1%). On the other hand, Norderhaug
et al.19 showed that prevalence of hematoma was less in the
Femostop group 7% vs. 11% in the MC group. Also, Semler21
reported that the incidence of hematoma was 2% using the
Compressor compared with 6% for MC. Non of the AFCD2
group had a large hematoma, however one patient in the
MC group had a large hematoma >5 cm.
Our trial represents a similar incidence of ecchymosis
between MC (32%) and AFCD (28%) in accordance with
Lehmann et al.27 who showed that the frequency of ecchymosis
formation was statistically similar between MC (38%) and
mechanical compression (34% for C-clamp and 29% for
Femostop).
The results of this trial signify oozing frequency to be statis-
tically similar between MC (4%) and AFCD (10%) in accor-
dance with Lehmann et al.27 that represent similar bleeding
rate between MC (8%) and mechanical compression (6% for
C-clamp and 12% for Femostop). On the other hand, Benson
et al.26 showed more signiﬁcant rebleeding 7/61 (11%) in
mechanical compression compared to zero/30 in the MC
group, which can be attributed to the lack of clear deﬁnition
of rebleeding in the MC group.
This trial had several limitations; The ACT was not moni-
tored in the current study.
However, as the patients were randomized, the intensity of
the anticoagulation during the procedure should have been
similar in the two arms of the trial. The nature of the trial pre-
cluded blinding of treatment strategy for either patient or
treating physician, though most outcomes were evaluated
without knowledge of the assigned technique. Cost-effective-
ness has not been examined in this trial, however, it is well
76 A.K.M. Hassan et al.known that locally developed device costs much less than any
commercially available one. Improvement of device design
with a C-shaped belt free device is a point for improvement
in the device for further easy and rapid application.
5. Conclusions
Our results indicate that AFCD2 is a simple and effective alter-
native to MC for hemostasis following PCI. Early sheath
removal 2 h. post PCI is feasible, safe, and improves the
patient’s comfort.
6. Future prospective
Next step is to develop AFCD3 with C-shaped belt free design
and use it in patients undergoing PCI. Aim is to study cost
effectiveness regarding expenses of the procedure and hospital
stay and also to study the feasibility of immediate sheath
removal post PCI.
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